Amarin Plc is a pharmaceutical company focused on developing and commercializing cardiovascular therapeutics, primarily VASCEPA, which reduces triglyceride levels in patients with severe hypertriglyceridemia. VASCEPA is marketed through wholesalers and specialty pharmacies.
Amarin (AMRN) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Amarin's actual EPS was -$0.76, missing the estimate of -$0.58 per share, resulting in a -30.72% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
